Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza.

ABSTRACT:

Unlabelled

The recent swine H1N1 influenza outbreak demonstrated that egg-based vaccine manufacturing has an Achille's heel: its inability to provide a large number of doses quickly. Using a novel manufacturing platform based on transient expression of influenza surface glycoproteins in Nicotiana benthamiana, we have recently demonstrated that a candidate Virus-Like Particle (VLP) vaccine can be generated within 3 weeks of release of sequence information. Herein we report that alum-adjuvanted plant-made VLPs containing the hemagglutinin (HA) protein of H5N1 influenza (A/Indonesia/5/05) can induce cross-reactive antibodies in ferrets. Even low doses of this vaccine prevented pathology and reduced viral loads following heterotypic lethal challenge. We further report on safety and imm

SUBMITTER: Landry N 

PROVIDER: S-EPMC3008737 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature